See more : Nippon Felt Co., Ltd. (3512.T) Income Statement Analysis – Financial Results
Complete financial analysis of Catheter Precision, Inc. (VTAK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Catheter Precision, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Armada Bilgisayar Sistemleri Sanayi ve Ticaret A.S. (ARMDA.IS) Income Statement Analysis – Financial Results
- Tecnos Japan Incorporated (3666.T) Income Statement Analysis – Financial Results
- Shaily Engineering Plastics Limited (SHAILY.NS) Income Statement Analysis – Financial Results
- Iberdrola, S.A. (IBE.MC) Income Statement Analysis – Financial Results
- Brødrene Hartmann A/S (HART.CO) Income Statement Analysis – Financial Results
Catheter Precision, Inc. (VTAK)
About Catheter Precision, Inc.
Catheter Precision, Inc. develops and delivers electrophysiology products to provide patients, hospitals, and physicians with technologies and solutions to improve the lives of patients with cardiac arrhythmias in the United States. The company's lead product is View into Ventricular Onset System, a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. It also provides LockeT, a suture retention device; and Amigo Remote Catheter System, a robotic arm that serves as a catheter control device. The company was formerly known as Ra Medical Systems, Inc and changed its name to Catheter Precision, Inc. in August 2023. Catheter Precision, Inc. is based in Fort Mill, South Carolina.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 442.00K | 14.00K | 22.00K | 4.41M | 7.20M | 6.26M | 5.87M | 5.98M |
| Cost of Revenue | 30.00K | 161.00K | 1.56M | 5.48M | 8.85M | 4.21M | 4.17M | 3.14M |
| Gross Profit | 412.00K | -147.00K | -1.54M | -1.08M | -1.65M | 2.05M | 1.71M | 2.84M |
| Gross Profit Ratio | 93.21% | -1,050.00% | -6,990.91% | -24.45% | -22.93% | 32.78% | 29.05% | 47.49% |
| Research & Development | 475.00K | 6.39M | 12.25M | 9.01M | 4.53M | 2.78M | 4.52M | 1.72M |
| General & Administrative | 0.00 | 2.23M | 0.00 | 25.97M | 51.55M | 30.44M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 1.25M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 17.12M | 16.25M | 15.48M | 25.97M | 51.55M | 30.44M | 14.95M | 5.32M |
| Other Expenses | 60.93M | 99.00K | 2.01M | 21.00K | 788.00K | 338.00K | 14.95M | 5.32M |
| Operating Expenses | 78.53M | 22.64M | 27.73M | 34.98M | 56.08M | 33.21M | 19.47M | 7.04M |
| Cost & Expenses | 78.56M | 22.80M | 29.29M | 40.46M | 64.93M | 37.42M | 23.63M | 10.17M |
| Interest Income | 347.00K | 0.00 | 0.00 | 129.00K | 1.04M | 352.00K | 0.00 | 0.00 |
| Interest Expense | 0.00 | 3.08M | 0.00 | 108.00K | 250.00K | 14.00K | 4.00K | 3.00K |
| Depreciation & Amortization | 2.08M | 421.00K | 1.40M | 2.00M | 1.75M | 624.00K | 218.00K | 95.00K |
| EBITDA | -15.11M | -22.37M | -27.70M | -33.30M | -54.94M | -30.18M | -17.54M | -4.10M |
| EBITDA Ratio | -3,418.55% | -129,971.43% | -133,027.27% | -818.59% | -801.92% | -498.00% | -298.84% | -68.66% |
| Operating Income | -78.12M | -26.96M | -29.27M | -36.06M | -57.73M | -31.16M | -17.76M | -4.20M |
| Operating Income Ratio | -17,673.98% | -192,578.57% | -133,027.27% | -818.59% | -801.92% | -498.00% | -302.56% | -70.25% |
| Total Other Income/Expenses | 7.55M | -4.07M | 2.01M | 88.00K | 788.00K | 338.00K | -4.00K | -3.00K |
| Income Before Tax | -70.57M | -26.86M | -27.26M | -36.04M | -56.94M | -30.82M | -17.76M | -4.20M |
| Income Before Tax Ratio | -15,966.52% | -191,871.43% | -123,895.45% | -818.12% | -790.97% | -492.60% | -302.62% | -70.30% |
| Income Tax Expense | 0.00 | 3.00K | 4.00K | 7.00K | 15.00K | 10.00K | 1.00K | 1.00K |
| Net Income | -70.57M | -26.87M | -25.07M | -36.05M | -56.96M | -30.83M | -17.77M | -4.20M |
| Net Income Ratio | -15,966.52% | -191,892.86% | -113,954.55% | -818.27% | -791.18% | -492.76% | -302.64% | -70.31% |
| EPS | -12.99 | -25.98 | -248.22 | -1.06K | -5.42K | -4.18K | -1.83K | -433.96 |
| EPS Diluted | -12.99 | -25.98 | -248.22 | -1.06K | -5.42K | -4.18K | -1.83K | -433.96 |
| Weighted Avg Shares Out | 5.50M | 1.03M | 101.00K | 33.98K | 10.52K | 7.38K | 9.68K | 9.68K |
| Weighted Avg Shares Out (Dil) | 5.50M | 1.03M | 101.00K | 33.98K | 10.52K | 7.38K | 9.68K | 9.68K |
Catheter Precision, Inc. Announces Effectiveness of 1-for-10 Reverse Stock Split
FORT MILLS, SC / ACCESSWIRE / July 15, 2024 / Catheter Precision, Inc. (NYSE American:VTAK), a US based innovative medical device company, announced today that its previously announced 1-for-10 reverse stock split of its common stock became effective at 12:01...
Catheter Precision, Inc. Announces Receipt of First Purchase Order for VIVO from Distributor in Middle East
FORT MILL, SC / ACCESSWIRE / June 20, 2024 / Catheter Precision, Inc. (the "Company") (NYSE American:VTAK), a US based innovative medical device company announced that it has received its first purchase order from Qatar. As previously announced, an initial...
Catheter Precision, Inc. Announces Receipt of LockeT Purchase Order for Eisenhower Medical Center, a Third California Hospital
FORT MILL, SC / ACCESSWIRE / June 17, 2024 / Catheter Precision, Inc. (the "Company") (NYSE American:VTAK), a US based innovative medical device company focused on electrophysiology products, announced an additional purchase order for its newest product, LockeT. As previously...
Catheter Precision, Inc. (NYSE: VTAK) Announces Initial Orders from Ronald Reagan UCLA Medical Center and Rady Children's Hospital in San Diego for LockeT
FORT MILL, SC / ACCESSWIRE / May 13, 2024 / Catheter Precision, Inc. (the "Company") (NYSE American:VTAK), a US based innovative medical device company focused on electrophysiology products, announced additional product evaluations for its newest product, LockeT. As previously announced,...
Catheter Precision, Inc. (VTAK) Announces Receipt of New Purchase Order and Product Evaluation at New Hospital
see attached FORT MILL, SC / ACCESSWIRE / May 7, 2024 / Catheter Precision, Inc. (the "Company") (NYSE American:VTAK), a US based innovative medical device company focused on electrophysiology products, announced the receipt of a purchase order for LockeT, the...
Catheter Precision, Inc. (NYSE American: VTAK) Reports Q1 2024 Highlights and Operational Performance Report
FORT MILL, SC / ACCESSWIRE / May 6, 2024 / Catheter Precision, Inc. (NYSE American:VTAK) a MedTech company pioneering products in the growing field of cardiac electrophysiology, including its VIVO™ and LockeT product(s), releases Q1 Financials, Operational Report for the...
Catheter Precision, Inc. (NYSE-American: VTAK) Announces New Chief Commercial Officer
FORT MILL, SC / ACCESSWIRE / May 1, 2024 / Catheter Precision, Inc. (NYSE American:VTAK), is pleased to announce and welcome Marie-Claude Jacques as Chief Commercial Officer. Marie-Claude will be responsible for the commercialization team including sales and marketing to...
Catheter Precision, Inc. (VTAK) Announces Receipt of First Purchase Order for LockeT from HCA Healthcare Facility
FORT MILL, SC / ACCESSWIRE / April 24, 2024 / Catheter Precision, Inc. (NYSE American:VTAK) ($VTAK), a leading MedTech company specializing in innovative products for cardiac electrophysiology, including its VIVO™ and LockeT products, announces that is has received its first...
Catheter Precision, Inc. (NYSE-American:VTAK) Expands Sales Team; Expects Corresponding Rise in Revenue Over the Near Term; Anticipates Breakeven by End of Year
FORT MILL, SC / ACCESSWIRE / April 4, 2024 / Catheter Precision, Inc. (NYSE American:VTAK), a leading MedTech company specializing in innovative products for cardiac electrophysiology, including its VIVO and LockeT products, has announced a major expansion in its business...
Catheter Precision, Inc. (NYSE American:VTAK) Releases Operational Performance Report, Q4 and Annual 2023 Financials for Year Ending December 31, 2023
FORT MILL, SC / ACCESSWIRE / April 1, 2024 / Catheter Precision, Inc. (NYSE-American:VTAK), a MedTech company pioneering products in the growing field of cardiac electrophysiology, including its VIVO™ and LockeT product(s), releases Q4 and Annual Financials, Operational Report for...
Source: https://incomestatements.info
Category: Stock Reports